Pomegra
AbbVie agrees to acquire Apogee Therapeutics in a $10.9 billion all-cash deal, its largest biotech M&A move since 2019, anchored by the IL-13 inhibitor zumilokibart for atopic dermatitis.
- AbbVie will pay $135.11 per share for Apogee, a 49% premium to the prior close of $90.38, in the company's largest deal since the Allergan acquisition.
- Lead asset zumilokibart (APG777), a half-life-extended IL-13 monoclonal antibody for atopic dermatitis, met all Phase 2 primary and secondary endpoints.
- The all-cash transaction closes in Q3 2026, pending Apogee shareholder and regulatory approval, and is projected accretive to adjusted EPS from 2032.
Lead
AbbVie announced Monday it has reached a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valuing the clinical-stage immunology company at approximately $10.9 billion. Under the terms of the deal, AbbVie will pay $135.11 per share, a premium of roughly 49% to Apogee's closing price of $90.38 on the prior session. The transaction, unanimously approved by the boards of both companies, is expected to close in the third quarter of 2026 and represents the largest biotech M&A move by AbbVie since its $63 billion acquisition of Allergan in 2020.What Happened
The agreement grants AbbVie full ownership of Apogee's multi-asset pipeline, which spans late-stage and early-stage programs across inflammatory and immunological diseases. The acquisition anchors on zumilokibart (APG777), a long-acting, half-life-extended monoclonal antibody inhibiting interleukin-13 (IL-13), a cytokine central to the inflammatory cascade driving moderate-to-severe atopic dermatitis and asthma. The Phase 2 APEX trial of zumilokibart met all primary and secondary endpoints with high statistical significance, and AbbVie plans to advance the mid-dose regimen into Phase 3 studies in the second half of 2026.
The pipeline extends beyond zumilokibart. APG273, a long-acting combination targeting both IL-13 and thymic stromal lymphopoietin (TSLP), is being advanced in asthma, representing a potential differentiated position against both existing IL-13 inhibitors and TSLP-targeting agents.
Market Reaction
AbbVie stock (ABBV) opened approximately 3.3% higher on June 22 following the announcement, a notable gain for a large-cap pharmaceutical company executing a near-$11 billion cash acquisition. The market response reflected investor confidence in the strategic logic rather than concern over balance-sheet impact. Apogee Therapeutics shares (APGE) surged toward the $135.11 offer price, confirming market acceptance of the premium and negligible deal-break speculation. The AbbVie Apogee acquisition drew comparisons to rival deal activity across the sector as large-cap pharma continues to deploy capital ahead of looming patent expirations.Strategic Context
The deal reflects AbbVie's disciplined effort to extend its immunology franchise into the next decade. AbbVie's immunology portfolio generated more than $30 billion in revenue in 2025, a 14% year-over-year increase, driven by blockbuster drugs Skyrizi and Rinvoq, which more than offset a 49% decline in Humira sales as biosimilar competition intensified following the drug's loss of exclusivity. Skyrizi and Rinvoq face their own eventual patent cliffs, making pipeline reinforcement a strategic priority.
Zumilokibart enters a competitive but large market. Dupixent, co-developed by Regeneron and Sanofi, has established atopic dermatitis as a multi-billion-dollar category, with the drug generating over $14 billion in annual revenue. Apogee's extended half-life formulation is designed to offer less-frequent dosing — a meaningful differentiation factor in a market where patient adherence and convenience strongly influence commercial uptake. AbbVie has positioned zumilokibart as a potential "mega-blockbuster," with accretion to adjusted diluted earnings per share expected beginning in 2032 as the asset progresses through Phase 3 and toward potential approval.
What Comes Next
The transaction requires Apogee shareholder approval and customary regulatory clearance. No material antitrust obstacles have been flagged given the distinct competitive positioning of Apogee's pipeline relative to AbbVie's existing assets. Phase 3 initiation for zumilokibart in atopic dermatitis is targeted for late 2026, keeping a potential regulatory submission on track for the early 2030s horizon — aligned with AbbVie's stated EPS accretion timeline.
For the broader biotech M&A landscape, the deal signals continued appetite among large-cap pharmaceutical acquirers to pay substantial premiums for late-clinical-stage immunology assets, particularly those offering next-generation dosing profiles against validated targets.
Outlook
AbbVie's acquisition of Apogee Therapeutics for $10.9 billion reinforces the company's position as the dominant force in inflammatory disease pharmacology and provides a credible long-term growth asset beyond its current Skyrizi and Rinvoq cycle. The deal's outcome hinges on zumilokibart's Phase 3 execution and the competitive dynamics of the atopic dermatitis market as it matures. A Q3 2026 close is expected, with commercial implications materializing in the early 2030s.
Deals }}
